Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

In drug-naïve subjects with type 2 diabetes ... The studies presented thus far therefore suggest that DPP-4 inhibition is an efficient treatment of type 2 diabetes, both as monotherapy and ...

Diabetes is very common in people living in post-acute and long-term environments, affecting 25% to 34% of these individuals.

Linagliptin, metformin HCl ext-rel; 2.5mg/1000mg, 5mg/1000mg; tabs. Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose ...

A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be ...

DPP-4 inhibitors help lower blood sugar levels only ... What is the experimental drug for type 2 diabetes? There are a number of new treatments for T2D that have recently become available to ...

History of angioedema to other DPP-4 inhibitors. Elderly, debilitated, uncompensated strenuous exercise, malnourished or deficient caloric intake, adrenal or pituitary insufficiency, or alcohol ...

Use of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs to treat type 2 diabetes may also help to lower the risk of ...

The rise in type 2 diabetes has become a significant public health concern in recent years. This form of diabetes happens ...

The researchers compared semaglutide to other GLP-1 drugs and the anti-diabetes medications insulin, metformin, DPP-4 inhibitors ... The US Food and Drug Administration approved Ozempic in ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...